aTYR PHARMA (ATYR) Common Equity (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Common Equity came in at $57.9 million in Q1 2026, down 22.61% YoY from $74.9 million in Q1 2025, and down 14.15% on a QoQ basis from $67.5 million in Q4 2025.
aTYR PHARMA (ATYR) Common Equity (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Common Equity data on file, last reported at $57.9 million in Q1 2026.
- Quarterly Common Equity fell 22.61% year-over-year to $57.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.9 million (down 22.61% YoY) and the FY2025 annual result came in at $67.5 million, down 3.37% from the prior year.
- Common Equity fell to $57.9 million in Q1 2026, from $67.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $109.7 million in Q1 2023 to a low of $57.9 million in Q1 2026.
- A 5-year average of $82.0 million and a median of $80.0 million in 2025 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 111.88% in 2022, down 34.68% in 2022.
- Tracing ATYR's Common Equity over 5 years: stood at $71.3 million in 2022, then gained by 26.91% to $90.5 million in 2023, then decreased by 22.81% to $69.8 million in 2024, then decreased by 3.37% to $67.5 million in 2025, then retreated by 14.15% to $57.9 million in 2026.
- The last three Common Equity figures came in at $57.9 million (Q1 2026), $67.5 million (Q4 2025), and $80.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 48.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.79 Mn |
| Mar 31, 2026 | 57.93 Mn |
| Dec 31, 2025 | 67.48 Mn |
| Sep 30, 2025 | 80.04 Mn |
| Jun 30, 2025 | 74.66 Mn |
| Mar 31, 2025 | 74.86 Mn |
| Dec 31, 2024 | 69.83 Mn |
| Sep 30, 2024 | 65.14 Mn |
| Jun 30, 2024 | 81.42 Mn |
| Mar 31, 2024 | 84.28 Mn |
| Dec 31, 2023 | 90.47 Mn |
| Sep 30, 2023 | 98.20 Mn |
| Jun 30, 2023 | 106.05 Mn |
| Mar 31, 2023 | 109.70 Mn |
| Dec 31, 2022 | 71.28 Mn |
| Sep 30, 2022 | 77.01 Mn |
| Jun 30, 2022 | 86.46 Mn |
| Mar 31, 2022 | 98.37 Mn |
| Dec 31, 2021 | 109.13 Mn |
| Sep 30, 2021 | 117.44 Mn |